Related references
Note: Only part of the references are listed.Increased receptor activity-modifying protein 1 in the nervous system is sufficient to protect against autonomic dysregulation and hypertension
Rasna Sabharwal et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2019)
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Tina Marie Myers Oakes et al.
CEPHALALGIA (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured
Christopher S. Walker et al.
CEPHALALGIA (2018)
Overview of Neuropeptides: Awakening the Senses?
Andrew F. Russo
HEADACHE (2017)
The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine
Lars Edvinsson
HEADACHE (2017)
Triptans and CGRP blockade - impact on the cranial vasculature
Silvia Benemei et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more
Paul W. H. I. Parren et al.
MABS (2017)
Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
Messoud Ashina et al.
NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries
Majid Sheykhzade et al.
VASCULAR PHARMACOLOGY (2017)
Antibody Engineering for Pursuing a Healthier Future
Abdullah F. U. H. Saeed et al.
FRONTIERS IN MICROBIOLOGY (2017)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
David Monteith et al.
FRONTIERS IN PHARMACOLOGY (2017)
Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs
Michael J. Woolley et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Amy R. Tso et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography
Sajedeh Eftekhari et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2016)
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
Susan Friend et al.
BMC NEUROLOGY (2016)
Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients
Peter J. Goadsby
BRAIN (2016)
Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development
Rebekah L. Bower et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage
Shawn M. Lamothe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients
Sarah Miller et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine
Andrew F. Russo
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody
William J. Breslin et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2015)
Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier
Sajedeh Eftekhari et al.
BRAIN RESEARCH (2015)
Therapeutic antibodies against CGRP or its receptor
Marcelo E. Bigal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Lars Edvinsson
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine
Guanglin Luo et al.
ORGANIC LETTERS (2015)
Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics
Danica B. Stanimirovic et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor
Christopher S. Walker et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
Steve Vermeersch et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Amylin: Pharmacology, Physiology, and Clinical Potential
Debbie L. Hay et al.
PHARMACOLOGICAL REVIEWS (2015)
Placental Transfer of a Fully Human IgG2 Monoclonal Antibody in the Cynomolgus Monkey, Rat, and Rabbit: A Comparative Assessment from during Organogenesis to Late Gestation
Graeme J. Moffat et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2014)
Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
Marcelo E. Bigal et al.
CNS DRUGS (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain
R. J. Benschop et al.
OSTEOARTHRITIS AND CARTILAGE (2014)
Assessment of fetal exposure risk following seminal excretion of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model
William J. Breslin et al.
REPRODUCTIVE TOXICOLOGY (2014)
Insights into the structure of class B GPCRs
Kaspar Hollenstein et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?
C. S. Walker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Pearls and pitfalls in neural CGRP immunohistochemistry
Karin Warfvinge et al.
CEPHALALGIA (2013)
Emerging Target-Based Paradigms to Prevent and Treat Migraine
S. D. Silberstein
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
Marcelo E. Bigal et al.
HEADACHE (2013)
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
Eva Cernuda-Morollon et al.
NEUROLOGY (2013)
In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
Eric D. Hostetler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine
Eric L. Moore et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
MECHANISMS OF DISEASE IgG4-Related Disease
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mechanisms of Monoclonal Antibody-Drug Interactions
Honghui Zhou et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Possible site of action of CGRP antagonists in migraine
Peer Tfelt-Hansen et al.
CEPHALALGIA (2011)
Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74
Philip S. Miller et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches
Lars Edvinsson et al.
CEPHALALGIA (2010)
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
Jakob Moller Hansen et al.
CEPHALALGIA (2010)
Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism
Ernst ter Haar et al.
STRUCTURE (2010)
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
Sajedeh Eftekhari et al.
Therapeutic Advances in Neurological Disorders (2010)
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review
Peer Tfelt-Hansen et al.
JOURNAL OF HEADACHE AND PAIN (2009)
How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations
Eva-Maria Jahn et al.
NEW BIOTECHNOLOGY (2009)
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs
Carlos M. Villalon et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells
Jing Li et al.
BRAIN RESEARCH (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Inhibition of calcitonin gene-related peptide function: A promising strategy for treating migraine
Paul L. Durham
HEADACHE (2008)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin:: Evaluation of a human in vivo pharmacodynamic model
B. J. Van der Schueren et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor
Debbie L. Hay et al.
PHARMACOLOGICAL REVIEWS (2008)
Crystal structure of the human receptor activity-modifying protein 1 extracellular domain
Seisuke Kusano et al.
PROTEIN SCIENCE (2008)
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
T. W. Ho et al.
NEUROLOGY (2008)
Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl)piperidine-1-carboxamide], a potent and orally Active calcitonin gene-related peptide receptor antagonist for the treatment of migraine
Christopher A. Salvatore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine:: Discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974)
Daniel V. Paone et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1
Madeleine Heroux et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion
Zhongming Zhang et al.
JOURNAL OF NEUROSCIENCE (2007)
GPCR modulation by RAMPS
DL Hay et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
No increase of calcitonin gene-related peptide in jugular blood during migraine
JF Tvedskov et al.
ANNALS OF NEUROLOGY (2005)
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists.: 1.: Potent and selective small molecule CGRP antagonists.: 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine:: The first CGRP antagonist for clinical trials in acute migraine
K Rudolf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Use of human germline genes in a CDR homology-based approach to antibody humanization
WYK Hwang et al.
METHODS (2005)
Mechanisms of peptide and nonpeptide ligand binding to class B G-protein coupled receptors
SRJ Hoare
DRUG DISCOVERY TODAY (2005)
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack
G Juhasz et al.
CEPHALALGIA (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Novel receptor partners and function of receptor activity-modifying proteins
A Christopoulos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty
DE Mager et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors
DR Poyner et al.
PHARMACOLOGICAL REVIEWS (2002)
Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists
JJ Mallee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
CGRP may play a causative role in migraine
LH Lassen et al.
CEPHALALGIA (2002)
Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells
L Edvinsson et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Transcytosis and catabolism of antibody
V Ghetie et al.
IMMUNOLOGIC RESEARCH (2002)
Neurogenic inflammation in the context of migraine
DJ Williamson et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2001)
Receptor activity modifying proteins
PM Sexton et al.
CELLULAR SIGNALLING (2001)
The vanilloid receptor: A molecular gateway to the pain pathway
MJ Caterina et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
Placental transfer of IgG subclasses in a Japanese population
S Hashira et al.
PEDIATRICS INTERNATIONAL (2000)
Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks
M Ashina et al.
PAIN (2000)
Share Paper
